Second Notice to Clarify Other Submission Requirements for the 2010 NIDA Translational Avant-Garde Award for Medication Development for Diseases of Addiction (DP1), RFA-DA-10-013

Notice Number: NOT-DA-10-013

Key Dates
Release Date: February 19, 2010

Issued by
National Institute on Drug Abuse (NIDA), (http://www.nida.nih.gov)

Purpose

The purpose of this Notice is to clarify language contained in three items in Section IV.6. Other Submission Requirements of the 2010 NIDA Translational Avant-Garde Award for Medication Development for Diseases of Addiction (DP1), RFA-DA-10-013 (http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-10-013.html).

Specifically,

  1. Section IV.6.2 R&R Other Project Information Component, Item Number 7. Project Summary/Abstract: should read

Attach abstract (not to exceed one page) describing the goals of the project.  The abstract must be substantially the same as that submitted in response to PAR-10-095.  Only minor changes, such as fixing typographical errors, will be allowed.  Text only – no figures, animations, or Web links are allowed.

The abstract should contain a brief statement describing how the proposed research project is ready for translation, how it can accelerate the development of new medications, and how it will have the potential for major practical impact.

  1. Section IV.6.2 R& R Other Project Information Component, Item Number 12. Other Attachments: 2) Essay: should read

The essay must be substantially the same as that submitted in the pre-application (X02) in response to PAR-10-095.  Using a maximum of 5 pages, compose an essay consisting of two key parts: (A) the Overall Translational Path and (B) the Individual Mission Plan.  The Overall Translational Path must demonstrate an understanding of the translational process and the research continuum from discoveries to patients.  It should also describe how the proposed research fits into the continuum.  The Individual Mission Plan must contain a sound research plan specifically indicating how this particular research will contribute to the translational process.  The proposed research must have entry and end points along the Translational Path.  References are not required but, if included, must fit within the 5 page limit.

Other sections of the FOAs remain unchanged.

Inquiries

For further information contact:

Elena Koustova, Ph.D.
Division of Basic Neuroscience and Behavioral Research
National Institute on Drug Abuse
National Institutes of Health
6001 Executive Blvd
Rm 4282 MSC 9555
Bethesda, MD 20892
Telephone: 301-496-8768
Fax: 301-594-6043
Email: koustovae@nida.nih.gov

Nora Chiang, Ph.D.
Division of Pharmacotherapies and Medical Consequences of Drug Abuse
Chemistry and Pharmaceutics Branch
National Institute on Drug Abuse
National Institutes of Health
6001 Executive Blvd
Rm 4123 MSC 9551
Bethesda, MD 20892
Telephone: 301-443-5280
Email: nchiang@nida.nih.gov


Weekly TOC for this Announcement
NIH Funding Opportunities and Notices


Office of Extramural Research (OER) - Home Page Office of Extramural
Research (OER)
  National Institutes of Health (NIH) - Home Page National Institutes of Health (NIH)
9000 Rockville Pike
Bethesda, Maryland 20892
  Department of Health and Human Services (HHS) - Home Page Department of Health
and Human Services (HHS)
  USA.gov - Government Made Easy


Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.